

Fig. 1S . $^1\text{H NMR}$ spectra of LCIP and LCIM perimidine ligands





Fig. 2S. Mass spectra of LNO₂ and LCIP ligands













Fig. 3 S. X-Ray patterns for four perimidine ligands







Fig. 4S . SEM images of perimidine ligands and their VO(II) complexes






Fig.6S . Interacting hp plot ; LH, LOMe,LNO₂,LCIPand LCIM with 4c3p(1) and 3bch(2) receptors(A-E, respectively)




Fig. 7S. 2D plot forms ; LH, LOMe, LNO₂, LCIP and LCIM with 4c3p (1), 3bch (2) and 4zdr (3) receptors (A-E, respectively)




Fig.8S . Dose response curves of perimidinone-VO(II) complexes against MCF-7, HCT-116 and HEPG-2 cancer cells